Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. (DRMA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · DRMA · as of Jun 8, 2026
Key Statistics
Explore Dermata Therapeutics, Inc. Data
drma stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
The DRMA analyst consensus is Buy, based on ratings from 1 Wall Street analysts over the past 3 months. The average 12-month price target is $6.00, representing +395.87% upside from the current price of $1.21.
Competitors & Peers
drma competitorsDRMA
ARTL
ATXI
CARM
ELAB
GTBPStock Performance
Full HistoryAbout Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic…
what is dermata therapeutics, inc. · drma stock overview · dermata therapeutics, inc. company profile · who is dermata therapeutics, inc. ceo · drma NASDAQ · dermata therapeutics, inc. headquarters · dermata therapeutics, inc. business segments
About Stock Overview & Key Data
Dermata Therapeutics, Inc. (DRMA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Aug 13, 2021. As of the latest trading session, DRMA stock price is $1.21, with a market capitalization of $828,092. The stock has returned -83.97% over the past 12 months and -47.63% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Dermata Therapeutics, Inc. stock is Buy, with an average 12-month price target of $6.00. In fiscal year 2025, Dermata Therapeutics, Inc. reported revenue of — and net income of -$7.6M. For detailed data — including Dermata Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Dermata Therapeutics, Inc. (DRMA) stock price is $1.21. The stock is traded on NASDAQ under the ticker symbol DRMA. The 52-week range is $1.10 – $8.00.